UFP-112 a Potent and Long-Lasting Agonist Selective for the Nociceptin/Orphanin FQ Receptor

CNS Neuroscience and Therapeutics

Volumn 17, Issue 3, 2011, Pages 178-198

  Calo', Girolamo ^a   Rizzi, Anna ^a   Cifani, Carlo ^b   Micioni Di Bonaventura, Maria Vittoria ^b   Regoli, Domenico ^a   Massi, Maurizio ^b   Salvadori, Severo ^a   Lambert, David G ^c   Guerrini, Remo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF CAMERINO   (Italy)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

In vitro and in vivo studies; Nociceptin orphanin FQ; NOP receptor; NOP( ) mice; Pharmacological profile; UFP 112

Indexed keywords

NOCICEPTIN RECEPTOR; NOCICEPTIN RECEPTOR AGONIST; UFP 112; UNCLASSIFIED DRUG;

CONCENTRATION (PARAMETERS); DRUG ACTIVITY; DRUG DESIGN; DRUG HALF LIFE; DRUG RESEARCH; DRUG STRUCTURE; ELECTROSTIMULATION; FOOD INTAKE; HUMAN; NONHUMAN; REVIEW; VAS DEFERENS;

EID: 79955711561     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2009.00107.x     Document Type: Review

References (160)

1. Jacoby E, Bouhelal R, Gerspacher M, Seuwen K. The 7 TM G-protein-coupled receptor target family. Chem Med Chem 2006;1:761-782.
2. Chung S, Funakoshi T, Civelli O. Orphan GPCR research. Br J Pharmacol 2008;153:S339-S346.
3. Lambert DG. The nociceptin/orphanin FQ receptor: A target with broad therapeutic potential. Nat Rev Drug Discov 2008;7:694-710.
4. Evans CJ, Keith DE, Jr., Morrison H, Magendzo K, Edwards RH. Cloning of a delta opioid receptor by functional expression. Science 1992;258:1952-1955.
5. Kieffer BL, Befort K, Gaveriaux-Ruff C, Hirth CG. The delta-opioid receptor: Isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci U S A 1992;89:12048-12052.
6. Yasuda K, Raynor K, Kong H, et al. Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc Natl Acad Sci U S A 1993;90:6736-6740.
7. Chen Y, Mestek A, Liu J, Hurley JA, Yu L. Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Mol Pharmacol 1993;44:8-12.
8. Mollereau C, Parmentier M, Mailleux P, et al. ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett 1994;341:33-38.
9. Bunzow JR, Saez C, Mortrud M, Bouvier C, Williams JT, Low M, Grandy DK. Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta or kappa opioid receptor type. FEBS Lett 1994;347:284-288.
10. Chen Y, Fan Y, Liu J, Mestek A, Tian M, Kozak CA, Yu L. Molecular cloning, tissue distribution and chromosomal localization of a novel member of the opioid receptor gene family. FEBS Lett 1994;347:279-283.
11. Wang JB, Johnson PS, Imai Y, Persico AM, Ozenberger BA, Eppler CM, Uhl GR. cDNA cloning of an orphan opiate receptor gene family member and its splice variant. FEBS Lett 1994;348:75-79.
12. Mollereau C, Mouledous L. Tissue distribution of the opioid receptor-like (ORL1) receptor. Peptides 2000;21:907-917.
13. Reinscheid RK, Nothacker HP, Bourson A, et al. Orphanin FQ: A neuropeptide that activates an opioidlike G protein-coupled receptor. Science 1995;270:792-794.
14. Meunier JC, Mollereau C, Toll L, et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 1995;377:532-535.
15. Mollereau C, Simons MJ, Soularue P, Liners F, Vassart G, Meunier JC, Parmentier M. Structure, tissue distribution, and chromosomal localization of the prepronociceptin gene. Proc Natl Acad Sci U S A 1996;93:8666-8670.
16. Nothacker HP, Reinscheid RK, Mansour A, et al. Primary structure and tissue distribution of the orphanin FQ precursor. Proc Natl Acad Sci U S A 1996;93:8677-8682.
17. Hawes BE, Graziano MP, Lambert DG. Cellular actions of nociceptin: Transduction mechanisms. Peptides 2000;21:961-967.
18. Cox BM, Chavkin C, Christie MJ, et al. Opioid receptors. In: Girdlestone D, editor. The IUPHAR compendium of receptor characterization and classification. second edition ed. London IUPHAR Media, 2000;321-333.
19. Koster A, Montkowski A, Schulz S, et al. Targeted disruption of the orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice. Proc Natl Acad Sci U S A 1999;96:10444-10449.
20. Nishi M, Houtani T, Noda Y, et al. Unrestrained nociceptive response and disregulation of hearing ability in mice lacking the nociceptin/orphaninFQ receptor. Embo J 1997;16:1858-1864.
21. Homberg JR, Mul JD, de Wit E, Cuppen E. Complete knockout of the nociceptin/orphanin FQ receptor in the rat does not induce compensatory changes in mu, delta and kappa opioid receptors. Neuroscience 2009;163:308-315.
22. Chiou LC, Liao YY, Fan PC, Kuo PH, Wang CH, Riemer C, Prinssen EP. Nociceptin/orphanin FQ peptide receptors: Pharmacology and clinical implications. Curr Drug Targets 2007;8:117-135.
23. Berzetei-Gurske IP, Schwartz RW, Toll L. Determination of activity for nociceptin in the mouse vas deferens. Eur J Pharmacol 1996;302:R1-2.
24. Calo G, Rizzi A, Bogoni G, et al. The mouse vas deferens: A pharmacological preparation sensitive to nociceptin. Eur J Pharmacol 1996;311:R3-5.
25. Dooley CT, Houghten RA. Orphanin FQ: Receptor binding and analog structure activity relationships in rat brain. Life Sci 1996;59:PL23-PL29.
26. Guerrini R, Calo G, Rizzi A, et al. Address and message sequences for the nociceptin receptor: A structure-activity study of nociceptin-(1-13)-peptide amide. J Med Chem 1997;40:1789-1793.
27. Calo G, Guerrini R, Bigoni R, Rizzi A, Bianchi C, Regoli D, Salvadori S. Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist. J Med Chem 1998;41:3360-3366.
28. Guerrini R, Calo G, Bigoni R, et al. Further studies on nociceptin-related peptides: discovery of a new chemical template with antagonist activity on the nociceptin receptor. J Med Chem 2000;43:2805-2813.
29. Guerrini R, Calo G, Bigoni R, et al. Structure-activity studies of the Phe(4) residue of nociceptin(1-13)-NH(2): identification of highly potent agonists of the nociceptin/orphanin FQ receptor. J Med Chem 2001;44:3956-3964.
30. Guerrini R, Calo G, Rizzi A, Bigoni R, Bianchi C, Salvadori S, Regoli D. A new selective antagonist of the nociceptin receptor. Br J Pharmacol 1998;123:163-165.
31. Calo G, Guerrini R, Bigoni R, et al. Characterization of [Nphe()]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist1. Br J Pharmacol 2000;129:1183-1193.
32. Bigoni R, Rizzi D, Rizzi A, et al. Pharmacological characterisation of [(pX)Phe4]nociceptin(1-13)amide analogues. 1. In vitro studies. Naunyn Schmiedebergs Arch Pharmacol 2002;365:442-449.
33. Rizzi A, Salis MB, Ciccocioppo R, et al. Pharmacological characterisation of [(pX)Phe4]nociceptin(1-13)NH2 analogues. 2. In vivo studies. Naunyn Schmiedebergs Arch Pharmacol 2002;365:450-456.
34. Okada K, Sujaku T, Chuman Y, et al. Highly potent nociceptin analog containing the Arg-Lys triple repeat. Biochem Biophys Res Commun 2000;278:493-498.
35. Calo G, Rizzi A, Rizzi D, et al. [Nphe1, Arg14, Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol 2002;136:303-311.
36. Calo G, Guerrini R, Rizzi A, et al. UFP-101, a Peptide Antagonist Selective for the Nociceptin/Orphanin FQ Receptor. CNS Drug Rev 2005;11:97-112.
37. Becker JA, Wallace A, Garzon A, et al. Ligands for kappa-opioid and ORL1 receptors identified from a conformationally constrained peptide combinatorial library. J Biol Chem 1999;274:27513-27522.
38. Dooley CT, Spaeth CG, Berzetei-Gurske IP, et al. Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1. J Pharmacol Exp Ther 1997;283:735-741.
39. Kawano C, Okada K, Honda T, Nose T, Sakaguchi K, Costa T, Shimohigashi Y. Structural requirements of nociceptin antagonist Ac-RYYRIK-NH2 for receptor binding. J Pept Sci 2002;8:561-569.
40. Judd AK, Kaushanskaya A, Tuttle DJ, Sanchez A, Khroyan T, Polgar W, Toll L. N-terminal modifications leading to peptide ORL1 partial agonists and antagonists. J Pept Res 2003;62:191-198.
41. Judd AK, Tuttle DJ, Jones RW, Sanchez A, Polgar W, Berzetei-Gurske I, Toll L. Structure-activity studies on high affinity NOP-active hexapeptides. J Pept Res 2004;64:87-94.
42. Carra G, Calo G, Spagnolo B, et al. Tryptophan replacement in the nociceptin/orphanin FQ receptor ligand Ac-RYYRWK-NH2. J Peptide Res 2005;66:39-47.
43. Gunduz O, Rizzi A, Baldisserotto A, et al. In vitro and in vivo pharmacological characterization of the nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-ol. Eur J Pharmacol 2006;539:39-48.
44. Gunduz O, Sipos F, Spagnolo B, et al. In vitro binding and functional studies of AcRYYRIK-ol and its derivatives, novel partial agonists of the nociceptin/orphanin FQ receptor. Neurosignals 2006;15:91-101.
45. Li J, Isozaki K, Okada K, Matsushima A, Nose T, Costa T, Shimohigashi Y. Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem 2008;16:2635-2644.
46. Thomsen C, Valsborg JS, Platou J, et al. [3H]ac-RYYRWK-NH2, a novel specific radioligand for the nociceptin/orphanin FQ receptor. Naunyn Schmiedebergs Arch Pharmacol 2000;362:538-545.
47. Kawano S, Ambo A, Sasaki Y. Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-amide. Bioorg Med Chem Lett 2006;16:4839-4841.
48. Rizzi A, Rizzi D, Marzola G, Regoli D, Larsen BD, Petersen JS, Calo G. Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: In vitro and in vivo studies in mice. Br J Pharmacol 2002;137:369-374.
49. Kapusta DR, Thorkildsen C, Kenigs VA, Meier E, Vinge MM, Quist C, Petersen JS. Pharmacodynamic characterization of ZP120 (Ac-RYYRWKKKKKKK-NH2), a novel, functionally selective nociceptin/orphanin FQ peptide receptor partial agonist with sodium-potassium-sparing aquaretic activity. J Pharmacol Exp Ther 2005;314:652-660.
50. Hadrup N, Petersen JS, Praetorius J, et al. Opioid receptor-like 1 stimulation in the collecting duct induces aquaresis through vasopressin-independent aquaporin-2 downregulation. Am J Physiol Renal Physiol 2004;287:F160-168.
51. Simonsen U, Laursen BE, Petersen JS. ZP120 causes relaxation by pre-junctional inhibition of noradrenergic neurotransmission in rat mesenteric resistance arteries. Br J Pharmacol 2008;153:1185-1194.
52. Fischetti C, Rizzi A, Gavioli EC, et al. Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor ligands ZP120. Peptides 2009;30:248-255.
53. Ozaki S, Kawamoto H, Itoh Y, et al. In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist. Eur J Pharmacol 2000;402:45-53.
54. Trapella C, Guerrini R, Piccagli L, et al. Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist. Bioorg Med Chem 2006;14:692-704.
55. Marti M, Trapella C, Morari M. The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: Positive interaction with L-DOPA. J Neurochem 2008;107:1683-1696.
56. Zaratin PF, Petrone G, Sbacchi M, et al. Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2, 6-dichlorophenyl)piperidin-1-yl]methyl]-6, 7, 8, 9- tetrahydro-5H-benzocyclohepten-5-ol (SB-612111). J Pharmacol Exp Ther 2004;308:454-461.
57. Spagnolo B, Carra G, Fantin M, et al. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-Methyl-7-[[4-(2, 6-dichlorophenyl)piperidin-1-yl]methyl]-6, 7, 8, 9-tetrahydro-5H-benzocyclohepten-5-ol]: In vitro studies. J Pharmacol Exp Ther 2007;321:961-967.
58. qi5. Naunyn Schmiedebergs Arch Pharmacol 2009;379:599-607.
59. Rizzi A, Gavioli EC, Marzola G, et al. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-Methyl-7-[[4-(2, 6-dichlorophenyl)piperidin-1-yl]methyl]-6, 7, 8, 9-tetrahydro-5H-benzocyclohepten-5-ol]: In vivo studies. J Pharmacol Exp Ther 2007;321:968-974.
60. Goto Y, Arai-Otsuki S, Tachibana Y, et al. Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity. J Med Chem 2006;49:847-849.
61. Yan-Yu L, Chiou LC. Effect of compound 24, a novel nociceptin/orphanin FQ (NOP) receptor antagonist, on NOP receptor-mediated k+ channel activation in rat periaqueductal gray slices. In: Society for Neuroscience; 2008 November 15-19, 2008; Washington, DC, USA; 2008.
62. Ruiz-Velasco V, Trapella C, Calo G, Margas W. Pharmacology of constitutively active NOP opioid receptors heterologously expressed in rat sympathetic neurons. In: Society for Neuroscience; 2008 November 15-19, 2008; Washington, DC, USA; 2008.
63. Fischetti C, Camarda V, Rizzi A, et al. Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24. Eur J Pharmacol 2009;614:50-57.
64. Wichmann J, Adam G, Rover S, Cesura AM, Dautzenberg FM, Jenck F. 8-acenaphthen-1-yl-1-phenyl-1, 3, 8-triaza-spiro[4.5]decan-4-one derivatives as orphanin FQ receptor agonists. Bioorg Med Chem Lett 1999;9:2343-2348.
65. Wichmann J, Adam G, Rover S, et al. Synthesis of (1S, 3aS)-8-(2, 3, 3a, 4, 5, 6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1, 3, 8-triaza-spiro[4. 5]decan-4-one, a potent and selective orphanin FQ (OFQ) receptor agonist with anxiolytic-like properties. Eur J Med Chem 2000;35:839-851.
66. Jenck F, Moreau JL, Martin JR, et al. Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress. Proc Natl Acad Sci U S A 1997;94:14854-14858.
67. Jenck F, Wichmann J, Dautzenberg FM, et al. A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: Anxiolytic profile in the rat. Proc Natl Acad Sci U S A 2000;97:4938-4943.
68. Dautzenberg FM, Wichmann J, Higelin J, et al. Pharmacological characterization of the novel nonpeptide orphanin FQ/nociceptin receptor agonist Ro 64-6198: Rapid and reversible desensitization of the ORL1 receptor in vitro and lack of tolerance in vivo. J Pharmacol Exp Ther 2001;298:812-819.
69. Shoblock JR. The pharmacology of Ro 64-6198, a systemically active, nonpeptide NOP receptor (opiate receptor-like 1, ORL-1) agonist with diverse preclinical therapeutic activity. CNS Drug Rev 2007;13:107-136.
70. Ho GD, Bercovici A, Tulshian D, et al. Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. Bioorg Med Chem Lett 2007;17:3028-3033.
71. Ho GD, Bercovici A, Tulshian D, Greenlee WJ, Fawzi A, Smith Torhan A, Zhang H. Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. Bioorg Med Chem Lett 2007;17:3023-3027.
72. Varty GB, Lu SX, Morgan CA, et al. The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510). J Pharmacol Exp Ther 2008;326:672-682.
73. Yang SW, Ho G, Tulshian D, et al. Structure-activity relationships of 3-substituted N-benzhydryl-nortropane analogs as nociceptin receptor ligands for the treatment of cough. Bioorg Med Chem Lett 2008;18:6340-6343.
74. Hayashi S, Hirao A, Imai A, Nakamura H, Murata Y, Ohashi K, Nakata E. Novel non-peptide nociceptin/orphanin FQ receptor agonist, 1-[1-(1-Methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole: Design, synthesis, and structure-activity relationship of oral receptor occupancy in the brain for orally potent antianxiety drug (1, 2). J Med Chem 2009;52:610-625.
75. Hirao A, Imai A, Sugie Y, Tamura T, Shimokawa H, Toide K. Pharmacological properties of a novel nociceptin/orphanin FQ receptor agonist, 2-(3, 5-dimethylpiperazin-1-yl)-1-[1-(1-methylcyclooctyl)piperidin-4-yl]-1H-benzim idazole, with anxiolytic potential. Eur J Pharmacol 2008;579:189-195.
76. Hirao A, Imai A, Sugie Y, Yamada Y, Hayashi S, Toide K. Pharmacological characterization of the newly synthesized nociceptin/orphanin FQ-receptor agonist 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole as an anxiolytic agent. J Pharmacol Sci 2008;106:361-368.
77. Reinscheid RK, Nothacker H, Civelli O. The orphanin FQ/nociceptin gene: Structure, tissue distribution of expression and functional implications obtained from knockout mice. Peptides 2000;21:901-906.
78. Zeilhofer HU, Calo G. Nociceptin/orphanin FQ and its receptor-potential targets for pain therapy? J Pharmacol Exp Ther 2003;306:423-429.
79. Gavioli EC, Calo G. Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands. Naunyn Schmiedebergs Arch Pharmacol 2006;372:319-330.
80. Olszewski PK, Levine AS. Minireview: Characterization of influence of central nociceptin/orphanin FQ on consummatory behavior. Endocrinology 2004;145:2627-2632.
81. Reinscheid RK. The Orphanin FQ/Nociceptin receptor as a novel drug target in psychiatric disorders. CNS Neurol Disord Drug Targets 2006;5:219-224.
82. Malinowska B, Godlewski G, Schlicker E. Function of nociceptin and opioid OP4 receptors in the regulation of the cardiovascular system. J Physiol Pharmacol 2002;53:301-324.
83. Lecci A, Giuliani S, Meini S, Maggi CA. Nociceptin and the micturition reflex. Peptides 2000;21:1007-1021.
84. McLeod RL, Bolser DC, Jia Y, et al. Antitussive effect of nociceptin/orphanin FQ in experimental cough models. Pulm Pharmacol Ther 2002;15:213-216.
85. Kapusta DR. Neurohumoral effects of orphanin FQ/nociceptin: Relevance to cardiovascular and renal function. Peptides 2000;21:1081-1099.
86. Ko MC, Wei H, Woods JH, Kennedy RT. Effects of intrathecally administered nociceptin/orphanin FQ in monkeys: Behavioral and mass spectrometric studies. J Pharmacol Exp Ther 2006;318:1257-1264.
87. Ko MC, Naughton NN. Antinociceptive effects of nociceptin/orphanin FQ administrered intrathecally in monkeys. J Pain 2009;10:509-516.
88. Viaro R, Sanchez-Pernaute R, Marti M, Trapella C, Isacson O, Morari M. Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism. Neurobiol Dis 2008;30:430-438.
89. Visanji NP, de Bie RM, Johnston TH, McCreary AC, Brotchie JM, Fox SH. The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 2008;23:1922-1925.
90. Lazzeri M, Calo G, Spinelli M, et al. Urodynamic and clinical evidence of acute inhibitory effects of intravesical nociceptin/orphanin FQ on detrusor overactivity in humans: A pilot study. J Urol 2001;166:2237-2240.
91. Lazzeri M, Calo G, Spinelli M, et al. Urodynamic effects of intravesical nociceptin/orphanin FQ in neurogenic detrusor overactivity: A randomized, placebo-controlled, double-blind study. Urology 2003;61:946-950.
92. Lazzeri M, Calo' G, Spinelli M, et al. Daily intravescical instillation of 1 mg nociceptin/orphanin FQ for the control of neurogenic detrusor overactivity - a multicenter, placebo controlled, randomized exploratory study. J Urol 2006;176:2098-2102.
93. Arduin M, Spagnolo B, Calo G, et al. Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with Calpha, alpha-dialkylated amino acids. Bioorg Med Chem 2007;15:4434-4443.
94. Rizzi A, Spagnolo B, Wainford RD, et al. In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor. Peptides 2007;28:1240-1251.
95. Varani K, Calo G, Rizzi A, et al. Nociceptin receptor binding in mouse forebrain membranes: Thermodynamic characteristics and structure activity relationships. Br J Pharmacol 1998;125:1485-1490.
96. Varani K, Rizzi A, Calo G, et al. Pharmacology of [Tyr1]nociceptin analogs: Receptor binding and bioassay studies. Naunyn Schmiedebergs Arch Pharmacol 1999;360:270-277.
97. Okawa H, Nicol B, Bigoni R, et al. Comparison of the effects of [Phe1psi(CH2-NH)Gly2]nociceptin(1-13)NH2 in rat brain, rat vas deferens and CHO cells expressing recombinant human nociceptin receptors. Br J Pharmacol 1999;127:123-130.
98. Bigoni R, Giuliani S, Calo G, et al. Characterization of nociceptin receptors in the periphery: In vitro and in vivo studies. Naunyn Schmiedebergs Arch Pharmacol 1999;359:160-167.
99. Calo G, Rizzi A, Bodin M, et al. Pharmacological characterization of nociceptin receptor: An in vitro study. Can J Physiol Pharmacol 1997;75:713-718.
100. Rizzi A, Calo G, Trevisani M, et al. Nociceptin receptor activation inhibits tachykinergic non adrenergic non cholinergic contraction of guinea pig isolated bronchus. Life Sci 1999;64:PL157-163.
101. Calo G, Bigoni R, Rizzi A, Guerrini R, Salvadori S, Regoli D. Nociceptin/orphanin FQ receptor ligands. Peptides 2000;21:935-947.
102. Rizzi A, Bigoni R, Marzola G, Guerrini R, Salvadori S, Regoli D, Calo G. Characterization of the locomotor activity-inhibiting effect of nociceptin/orphanin FQ in mice. Naunyn Schmiedebergs Arch Pharmacol 2001;363:161-165.
103. Bertorelli R, Corradini L, Rafiq K, Tupper J, Calo G, Ongini E. Nociceptin and the ORL-1 ligand [Phe1psi (CH2-NH)Gly2]nociceptin(1-13)NH2 exert anti-opioid effects in the Freund's adjuvant-induced arthritic rat model of chronic pain. Br J Pharmacol 1999;128:1252-1258.
104. Albrecht E, Samovilova NN, Oswald S, Baeger I, Berger H. Nociceptin (orphanin FQ): High-affinity and high-capacity binding site coupled to low-potency stimulation of guanylyl-5'-O-(gamma-thio)-triphosphate binding in rat brain membranes. J Pharmacol Exp Ther 1998;286:896-902.
105. Sandin J, Georgieva J, Silberring J, Terenius L. In vivo metabolism of nociceptin/orphanin FQ in rat hippocampus. Neuroreport 1999;10:71-76.
106. Madeddu P, Salis MB, Milia AF, Emanueli C, Guerrini R, Regoli D, Calo G. Cardiovascular effects of nociceptin in unanesthetized mice. Hypertension 1999;33:914-919.
107. Guerrini R, Calo G, Lambert DG, et al. N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands. J Med Chem 2005;48:1421-1427.
108. Zhang C, Miller W, Valenzano KJ, Kyle DJ. Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem 2002;45:5280-5286.
109. Toniolo C, Crisma M, Formaggio E, et al. Structures of peptides from alpha amino acids methylated at the alpha carbon. Biopolymers 1993;33:1061-1072.
110. Tancredi T, Carra G, Guerrini R, et al. The Interaction of Highly Helical Structural Mutants with the NOP Receptor Discloses the Role of the Address Domain of Nociceptin/Orphanin FQ. Chemistry 2005;11:2061-2070.
111. Reinscheid RK, Ardati A, Monsma FJ, Jr., Civelli O. Structure-activity relationship studies on the novel neuropeptide orphanin FQ. J Biol Chem 1996;271:14163-14168.
112. Topham CM, Mouledous L, Poda G, Maigret B, Meunier JC. Molecular modelling of the ORL1 receptor and its complex with nociceptin. Protein Eng 1998;11:1163-1179.
113. Rizzi D, Rizzi A, Bigoni R, et al. [Arg(14), Lys(15)]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies. J Pharmacol Exp Ther 2002;300:57-63.
114. Okada K, Isozaki K, Li J, Matsushima A, Nose T, Costa T, Shimohigashi Y. Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem 2008;16:9261-9267.
115. D'Agostino B, Orlotti D, Calo G, et al. Nociceptin modulates bronchoconstriction induced by sensory nerve activation in mouse lung. Am J Respir Cell Mol Biol 2010;42:250-254.
116. Rizzi D, Bigoni R, Rizzi A, et al. Effects of Ro 64-6198 in nociceptin/orphanin FQ-sensitive isolated tissues. Naunyn Schmiedebergs Arch Pharmacol 2001;363:551-555.
117. Chang M, Peng YL, Dong SL, et al. Structure-activity studies on different modifications of nociceptin/orphanin FQ: Identification of highly potent agonists and antagonists of its receptor. Regul Pept 2005;130:116-122.
118. Calo G, Rizzi A, Marzola G, et al. Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay. Br J Pharmacol 1998;125:373-378.
119. Nazzaro C, Rizzi A, Salvadori S, Guerrini R, Regoli D, Zeilhofer HU, Calo G. UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ: Behavioral and electrophysiological studies in mice. Peptides 2007;28:663-669.
120. Devine DP, Taylor L, Reinscheid RK, Monsma FJ, Jr., Civelli O, Akil H. Rats rapidly develop tolerance to the locomotor-inhibiting effects of the novel neuropeptide orphanin FQ. Neurochem Res 1996;21:1387-1396.
121. Marti M, Mela F, Veronesi C, et al. Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. J Neurosci 2004;24:6659-6666.
122. Marti M, Mela F, Fantin M, et al. Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J Neurosci 2005;25:9591-9601.
123. Marti M, Mela F, Guerrini R, Calo G, Bianchi C, Morari M. Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release. J Neurochem 2004;91:1501-1504.
124. Marti M, Trapella C, Viaro R, Morari M. The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. J Neurosci 2007;27:1297-1307.
125. Morari M, Calo G, Marti M. Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. In: Society for Neuroscience; 2007 November 3-7, 2007; San Diego, CA, USA; 2007. p. 892.815/R898.
126. Przydzial MJ, Heisler LK. Nociceptin/orphanin FQ peptide receptor as a therapeutic target for obesity. Mini Rev Med Chem 2008;8:796-811.
127. Economidou D, Policani F, Angellotti T, Massi M, Terada T, Ciccocioppo R. Effect of novel NOP receptor ligands on food intake in rats. Peptides 2006;27:775-783.
128. Devine DP, Reinscheid RK, Monsma FJ, Jr., Civelli O, Akil H. The novel neuropeptide orphanin FQ fails to produce conditioned place preference or aversion. Brain Res 1996;727:225-229.
129. Ciccocioppo R, Panocka I, Polidori C, Regoli D, Massi M. Effect of nociceptin on alcohol intake in alcohol-preferring rats. Psychopharmacology (Berl) 1999;141:220-224.
130. Ciccocioppo R, Polidori C, Antonelli L, Salvadori S, Guerrini R, Massi M. Pharmacological characterization of the nociceptin receptor which mediates reduction of alcohol drinking in rats. Peptides 2002;23:117-125.
131. Ciccocioppo R, Economidou D, Fedeli A, Angeletti S, Weiss F, Heilig M, Massi M. Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behaviour by the antiopioid peptide nociceptin/orphanin FQ in alcohol-preferring rats. Psychopharmacology (Berl) 2004;172:170-178.
132. Economidou D, Hansson AC, Weiss F, et al. Dysregulation of nociceptin/orphanin FQ activity in the amygdala is linked to excessive alcohol drinking in the rat. Biol Psychiatry 2008;64:211-218.
133. Roberto M, Siggins GR. Nociceptin/orphanin FQ presynaptically decreases GABAergic transmission and blocks the ethanol-induced increase of GABA release in central amygdala. Proc Natl Acad Sci U S A 2006;103:9715-9720.
134. Economidou D, Fedeli A, Fardon RM, Weiss F, Massi M, Ciccocioppo R. Effect of novel nociceptin/orphanin FQ-NOP receptor ligands on ethanol drinking in alcohol-preferring msP rats. Peptides 2006;27:3299-3306.
135. Ciccocioppo R, Economidou D, Rimondini R, Sommer W, Massi M, Heilig M. Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system. Biol Psychiatry 2007;61:4-12.
136. Kuzmin A, Sandin J, Terenius L, Ogren SO. Acquisition, expression, and reinstatement of ethanol-induced conditioned place preference in mice: Effects of opioid receptor-like 1 receptor agonists and naloxone. J Pharmacol Exp Ther 2003;304:310-318.
137. Kuzmin A, Kreek MJ, Bakalkin G, Liljequist S. The nociceptin/orphanin FQ receptor agonist Ro 64-6198 reduces alcohol self-administration and prevents relapse-like alcohol drinking. Neuropsychopharmacology 2007;32:902-910.
138. Osinski MA, Brown DR. Orphanin FQ/nociceptin: A novel neuromodulator of gastrointestinal function? Peptides 2000;21:999-1005.
139. Menzies JR, Corbett AD. Nociceptin inhibits tonic nitric oxide release in the mouse isolated proximal colon. Eur J Pharmacol 2000;388:183-186.
140. Broccardo M, Guerrini R, Morini G, Polidori C, Agostini S, Petrella C, Improta G. The gastric effects of UFP-112, a new nociceptin/orphanin receptor agonist, in physiological and pathological conditions. Peptides 2007;28:1974-1981.
141. Grandi D, Solenghi E, Guerrini R, Polidori C, Massi M, Morini G. Nociceptin/orphanin FQ prevents gastric damage induced by cold-restraint stress in the rat by acting in the periphery. Peptides 2007;28:1572-1579.
142. Broccardo M, Agostini S, Petrella C, Guerrini R, Improta G. Central and peripheral role of the nociceptin/orphaninFQ system on normal and disturbed colonic motor function and faecal pellet output in the rat. Neurogastroenterol Motil 2008;20:939-948.
143. Peng YL, Chang M, Dong SL, et al. Novel potent agonist [(pF)Phe4, Aib7, Aib11, Arg14, Lys15]N/OFQ-NH2 and antagonist [Nphe1, (pF)Phe4, Aib7, Aib11, Arg14, Lys15]N/OFQ-NH2 of nociceptin/orphanin FQ receptor. Regul Pept 2006;134:75-81.
144. Ciccocioppo R, Angeletti S, Panocka I, Massi M. Nociceptin/orphanin FQ and drugs of abuse. Peptides 2000;21:1071-1080.
145. Ciccocioppo R, Cippitelli A, Economidou D, Fedeli A, Massi M. Nociceptin/orphanin FQ acts as a functional antagonist of corticotropin-releasing factor to inhibit its anorectic effect. Physiol Behav 2004;82:63-68.
146. Agostini S, Eutamene H, Broccardo M, et al. Peripheral anti-nociceptive effect of nociceptin/orphanin FQ in inflammation and stress-induced colonic hyperalgesia in rats. Pain 2009;141:292-299.
147. Williams JA, Day M, Heavner JE. Ziconotide: an update and review. Expert Opin Pharmacother 2008;9:1575-1583.
148. Xu XJ, Hao JX, Wiesenfeld-Hallin Z. Nociceptin or antinociceptin: Potent spinal antinociceptive effect of orphanin FQ/nociceptin in the rat. Neuroreport 1996;7:2092-2094.
149. Erb K, Liebel JT, Tegeder I, Zeilhofer HU, Brune K, Geisslinger G. Spinally delivered nociceptin/orphanin FQ reduces flinching behaviour in the rat formalin test. Neuroreport 1997;8:1967-1970.
150. Kapusta DR, Sezen SF, Chang JK, Lippton H, Kenigs VA. Diuretic and antinatriuretic responses produced by the endogenous opioid-like peptide, nociceptin (orphanin FQ). Life Sci 1997;60:PL15-21.
151. Kapusta DR, Burmeister MA, Calo G, Guerrini R, Gottlieb HB, Kenigs VA. Functional selectivity of nociceptin/orphanin FQ peptide receptor partial agonists on cardiovascular and renal function. J Pharmacol Exp Ther 2005;314:643-651.
152. Sandin J, Georgieva J, Schott PA, Ogren SO, Terenius L. Nociceptin/orphanin FQ microinjected into hippocampus impairs spatial learning in rats. Eur J Neurosci 1997;9:194-197.
153. Manabe T, Noda Y, Mamiya T, et al. Facilitation of long-term potentiation and memory in mice lacking nociceptin receptors. Nature 1998;394:577-581.
154. Giuliani S, Lecci A, Tramontana M, Maggi CA. The inhibitory effect of nociceptin on the micturition reflex in anaesthetized rats. Br J Pharmacol 1998;124:1566-1572.
155. Murphy NP, Lee Y, Maidment NT. Orphanin FQ/nociceptin blocks acquisition of morphine place preference. Brain Res 1999;832:168-170.
156. McLeod RL, Parra LE, Mutter JC, et al. Nociceptin inhibits cough in the guinea-pig by activation of ORL(1) receptors. Br J Pharmacol 2001;132:1175-1178.
157. Redrobe JP, Calo G, Regoli D, Quirion R. Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test. Naunyn Schmiedebergs Arch Pharmacol 2002;365:164-167.
158. Gavioli EC, Marzola G, Guerrini R, et al. Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test. Eur J Neurosci 2003;17:1987-1990.
159. Carvalho D, Petronilho F, Vuolo F, et al. The nociceptin/orphanin FQ-NOP receptor antagonist effects on an animal model of sepsis. Intensive Care Med 2008;34:2284-2290.
160. Williams JP, Thompson JP, Young SP, Gold SJ, McDonald J, Rowbotham DJ, Lambert DG. Nociceptin and urotensin-II concentrations in critically ill patients with sepsis. Br J Anaesth 2008;100:810-814.